Tuesday, May 27, 2025
8:00 am Check In & Morning Coffee
Workshop A
9:00 am Exploring the Capabilities of Current AI Algorithms to Drive Retinal Imaging Biomarkers
Synopsis
With the exponential growth of computing power, the potential to revolutionize ophthalmology through advanced analysis of existing optical imaging data is unparalleled. This transformative synergy could unlock groundbreaking insights, redefine diagnostics, and pave the way for personalized treatments like never before. This workshop will provide an in-depth exploration of the breadth of AI technologies and how they are transforming the retinal imaging landscape and delivering value across clinical and research settings.
This workshop will:
- Review the accuracy and validity of AI models for retinal biomarkers and clinical trial design
- Examine the potential of regulatory-ready algorithms to deliver actionable insights within shorter trial timeframes
- Discuss the standardization of data sets and tools to ensure consistent quality and reproducibility
- Assess AI’s role as a screening versus diagnostic tool in clinical trials and patient care
- Identify the most impactful AI algorithms and their capabilities for lesion analysis, ellipsoid zone assessment, and for rare ophthalmic diseases
12:00 pm Networking Lunch
Workshop B
1:00 pm Identifying Clinically Meaningful Endpoints to Accelerate Retinal Disease Trials
Synopsis
With a lack of clinical endpoints that are relevant to both regulatory agencies, this workshop will explore the most clinically relevant biomarkers and endpoints that can drive progress in retinal disease therapies. Participants will gain insights into the latest technologies, challenges, and innovations for identifying meaningful endpoints in clinical trials.
This workshop will:
- Evaluate the balance between the cost and clinical relevance of advanced imaging techniques and their integration with clinical endpoints
- Analyze the potential for AI algorithms to segment and quantify retinal disease features that correlate with clinically meaningful improvements
- Discuss the utility of imaging biomarkers for surrogate endpoints in accelerated approval pathways
- Invest the relationship between structural markers and functional tests for better outcome prediction
- Explore the role of fluorescence lifetime imaging and other emerging tools for predicting disease progression and differentiating stages of geographic atrophy
- Assess how imaging endpoints may vary between early and late-stage diseases and their potential for mapping structural changes to functional tests